Practice Change With Drug-coated Balloon in Patients With multiVessel Coronary Artery Disease

Summary

This study is a prospective, multicenter, open-label, observational study to investigate the impact of using drug-coated balloons (DCBs) in the treatment of coronary artery lesions in patients with multivessel coronary artery disease (MVD), as opposed to the default strategy of using only drug-eluting stents (DES). The investigators aim to assess changes in clinical practice towards a hybrid treatment strategy (DES and DCB) and its effects on clinical outcomes.

Conditions

• Coronary Artery Disease
• Multi Vessel Coronary Artery Disease

Interventions

DEVICE

drug-coated balloon

For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.

DEVICE

drug-eluting stent

When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.

Sponsors & Collaborators

• Seoul National University Hospital

  collaborator OTHER

• St Vincent's Hospital

  collaborator OTHER

• Uijeongbu St. Mary Hospital

  collaborator OTHER

• Gachon University Gil Medical Center

  collaborator OTHER

• Gangnam Severance Hospital

  collaborator OTHER

• Kyunghee University Medical Center

  collaborator OTHER

• Keimyung University Dongsan Medical Center

  collaborator OTHER

• Inje University Ilsan Paik Hospital

  collaborator OTHER

• Daegu Catholic University Medical Center

  collaborator OTHER

• Sejong General Hospital

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• Soonchunhyang University Hospital

  collaborator OTHER

• Yeungnam University Hospital

  collaborator OTHER

• Wonju Severance Christian Hospital

  collaborator OTHER

• Ulsan University Hospital

  collaborator OTHER

• Ewha Womans University Mokdong Hospital

  collaborator OTHER

• Inje University

  collaborator OTHER

• Chonnam National University Hospital

  collaborator OTHER

• Chung-Ang University Gwangmyeong Hospital

  collaborator OTHER

• Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  collaborator OTHER

• Ulsan Medical Center

  collaborator OTHER

• Hanyang University Seoul Hospital

  collaborator OTHER

• Jeju National University Hospital

  collaborator OTHER

• KangWon National University Hospital

  collaborator OTHER

• Uijeongbu Eulji Medical Center, Eulji University

  collaborator UNKNOWN

• Seoul St. Mary's Hospital

  collaborator OTHER

• Gyeongsang National University Hospital

  collaborator OTHER

• Severance Hospital

  collaborator OTHER

• Chosun University Hospital

  collaborator OTHER

• Kyungpook National University Hospital

  collaborator OTHER

• Korea University Anam Hospital

  collaborator OTHER

• Kyung Hee University Hospital at Gangdong

  collaborator OTHER

• Ajou University School of Medicine

  collaborator OTHER

• Bon-Kwon Koo

  lead OTHER

Principal Investigators

• Bon-Kwon Koo, MD, PhD · +82-2-2072-2062

Eligibility

Min Age

19 Years

Max Age

100 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-09-18

Primary Completion

2025-08-31

Completion

2026-10-31

Countries

• South Korea

Study Locations